Cargando…

Quasi-Drugs Developed in Japan for the Prevention or Treatment of Hyperpigmentary Disorders

Excess production of melanin or its abnormal distribution, or both, can cause irregular hyperpigmentation of the skin, leading to melasma and age spots. To date, various quasi-drugs that prevent or improve hyperpigmentary disorders have been developed and officially approved by the Ministry of Healt...

Descripción completa

Detalles Bibliográficos
Autores principales: Ando, Hideya, Matsui, Mary S., Ichihashi, Masamitsu
Formato: Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2904932/
https://www.ncbi.nlm.nih.gov/pubmed/20640168
http://dx.doi.org/10.3390/ijms11062566
_version_ 1782183924929134592
author Ando, Hideya
Matsui, Mary S.
Ichihashi, Masamitsu
author_facet Ando, Hideya
Matsui, Mary S.
Ichihashi, Masamitsu
author_sort Ando, Hideya
collection PubMed
description Excess production of melanin or its abnormal distribution, or both, can cause irregular hyperpigmentation of the skin, leading to melasma and age spots. To date, various quasi-drugs that prevent or improve hyperpigmentary disorders have been developed and officially approved by the Ministry of Health, Labor and Welfare of Japan. Many of these inhibit the activity of tyrosinase, an enzyme required for melanin synthesis, for example, by competitive or non-competitive inhibition of its catalytic activity, by inhibiting its maturation, or by accelerating its degradation. In this review, we categorize the quasi-drugs developed in Japan to prevent or treat hyperpigmentary disorders, or both, and discuss perspectives for future development.
format Text
id pubmed-2904932
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Molecular Diversity Preservation International (MDPI)
record_format MEDLINE/PubMed
spelling pubmed-29049322010-07-16 Quasi-Drugs Developed in Japan for the Prevention or Treatment of Hyperpigmentary Disorders Ando, Hideya Matsui, Mary S. Ichihashi, Masamitsu Int J Mol Sci Review Excess production of melanin or its abnormal distribution, or both, can cause irregular hyperpigmentation of the skin, leading to melasma and age spots. To date, various quasi-drugs that prevent or improve hyperpigmentary disorders have been developed and officially approved by the Ministry of Health, Labor and Welfare of Japan. Many of these inhibit the activity of tyrosinase, an enzyme required for melanin synthesis, for example, by competitive or non-competitive inhibition of its catalytic activity, by inhibiting its maturation, or by accelerating its degradation. In this review, we categorize the quasi-drugs developed in Japan to prevent or treat hyperpigmentary disorders, or both, and discuss perspectives for future development. Molecular Diversity Preservation International (MDPI) 2010-06-18 /pmc/articles/PMC2904932/ /pubmed/20640168 http://dx.doi.org/10.3390/ijms11062566 Text en © 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0 This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Ando, Hideya
Matsui, Mary S.
Ichihashi, Masamitsu
Quasi-Drugs Developed in Japan for the Prevention or Treatment of Hyperpigmentary Disorders
title Quasi-Drugs Developed in Japan for the Prevention or Treatment of Hyperpigmentary Disorders
title_full Quasi-Drugs Developed in Japan for the Prevention or Treatment of Hyperpigmentary Disorders
title_fullStr Quasi-Drugs Developed in Japan for the Prevention or Treatment of Hyperpigmentary Disorders
title_full_unstemmed Quasi-Drugs Developed in Japan for the Prevention or Treatment of Hyperpigmentary Disorders
title_short Quasi-Drugs Developed in Japan for the Prevention or Treatment of Hyperpigmentary Disorders
title_sort quasi-drugs developed in japan for the prevention or treatment of hyperpigmentary disorders
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2904932/
https://www.ncbi.nlm.nih.gov/pubmed/20640168
http://dx.doi.org/10.3390/ijms11062566
work_keys_str_mv AT andohideya quasidrugsdevelopedinjapanforthepreventionortreatmentofhyperpigmentarydisorders
AT matsuimarys quasidrugsdevelopedinjapanforthepreventionortreatmentofhyperpigmentarydisorders
AT ichihashimasamitsu quasidrugsdevelopedinjapanforthepreventionortreatmentofhyperpigmentarydisorders